Search Within

Anas Younes

Formats
  1. Meeting Abstract (153)
  2. Journal Article (136)
  3. Book Section (13)
  4. Book Whole (4)
  5. Editorial (4)
  6. Review (4)
  7. Conference Paper (2)
  8. Research Letter (2)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (320)
  2. Department of Medicine (320)
  3. Executive Committee, Center for Hematologic Malignancies (320)
  4. Hematologic Malignancies, Division of (320)
  5. Lymphoma (320)
  6. Hematology-Oncology Fellows (98)

More Groups

People
  1. Andrew Zelenetz (89)
  2. Connie Batlevi (81)
  3. David Straus (74)
  4. Matthew Matasar (68)
  5. Anita Kumar (67)
  6. Paul Hamlin (67)

More People

Years
  1. 2024 (3)
  2. 2023 (7)
  3. 2022 (11)
  4. 2021 (13)
  5. 2020 (26)
  6. 2019 (53)

More Years

Publications
  1. Blood (91)
  2. Journal of Clinical Oncology (25)
  3. Hematological Oncology (22)
  4. Haematologica (16)
  5. British Journal of Haematology (13)
  6. Cancer Research (10)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. American Society of Clinical Oncology (27)
  3. Wiley Blackwell (25)
  4. Nature Publishing Group (19)
  5. Springer (17)
  6. American Association for Cancer Research (16)

More Publishers

Results (320)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
    Journal Article

    Kumar, A.; Vardhana, S.; Moskowitz, A. J.; Porcu, P.; Dogan, A.; Dubovsky, J. A.; Matasar, M. J.; Zhang, Z.; Younes, A.; Horwitz, S. M.
    Blood Advances (2018)

    Fulltext@MSK | Save
  • A pooled analysis of relapsed/refractory diffuse large B-cell lymphoma patients treated with the duel PI3K and HDAC inhibitor fimepinostat (CUDC-907), including patients with MYC-altered disease
    Meeting Abstract

    Landsburg, D. J.; Ramchandren, R.; Lugtenburg, P. J.; Kelly, K. R.; Younes, A.; Gharavi, R.; Tuck, D. P.; Barta, S. K.
    Blood (2018)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Nivolumab treatment beyond investigator-assessed progression: Extended follow-up in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study
    Meeting Abstract

    Cohen, J. B.; Kuruvilla, J.; Engert, A.; Ansell, S. M.; Younes, A.; Lee, H. J.; Trnený, M.; Savage, K. J.; Ramchandren, R.; Collins, G. P.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Preclinical activity of IRAK4 kinase inhibitor CA-4948 alone or in combination with targeted therapies and preliminary phase 1 clinical results in non-Hodgkin lymphoma
    Meeting Abstract

    Booher, R. N.; Nowakowski, G. S.; Patel, K.; Lunning, M. A.; Samson, M. E. S.; Atoyan, R.; Ma, A. W.; Xu, G. X.; Dellarocca, S.; Modafferi, H.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Nivolumab for relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic cell transplantation (auto-HCT): Extended follow-up of the phase 2 single-arm CheckMate 205 study
    Meeting Abstract

    Armand, P.; Engert, A.; Younes, A.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Timmerman, J. M.; Collins, G. P.; Ramchandren, R.; Cohen, J. B.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; De Frank, S.; Stewart, C.; Hamlin, P. A.; Matasar, M. J.; Gerecitano, J. F.; Moskowitz, A. J.; Hamilton, A. M.; Zelenetz, A. D.; Drullinsky, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
    Journal Article

    Liu, Y.; Mondello, P.; Erazo, T.; Tannan, N. B.; Asgari, Z.; de Stanchina, E.; Nanjangud, G.; Seshan, V. E.; Wang, S.; Wendel, H. G.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save
  • STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial
    Journal Article

    Reilley, M. J.; McCoon, P.; Cook, C.; Lyne, P.; Kurzrock, R.; Kim, Y.; Woessner, R.; Younes, A.; Nemunaitis, J.; Fowler, N.; more...
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Hodgkin lymphoma: Clinical manifestations, staging, and therapy
    Book Section

    Smith, K.; Chiu, A.; Parikh, R.; Yahalom, J.; Younes, A.
    In Hoffman, R.; Benz, E. J. Jr; Silberstein, L. E.; Heslop, H. E.; Weitz, J. I.; Anastasi, J.; Salama, M. E.; Abutalib, S. A. (Eds.) Hematology: Basic Principles and Practice. 7th ed (2018)

    Fulltext@MSK | Save